Cognitive impairment in Alzheimer's disease FAD<sup>4T</sup> mouse model: Synaptic loss facilitated by activated microglia via C1qA.

Life sciences 2024
Open on PubMed

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder characterized by cognitive dysfunction. The connection between neuroinflammation and abnormal synaptic function in AD is recognized, but the underlying mechanisms remain unclear. In this study, we utilized a mouse model of AD, FAD<sup>4T</sup> mice aged 6-7&#xa0;months, to investigate the molecular changes affecting cognitive impairment. Behavior tests showed that FAD<sup>4T</sup> mice exhibited impaired spatial memory compared with their wild-type littermates. Immunofluorescence staining revealed the presence of A&#x3b2; plaques and abnormal glial cell activation as well as changes in microglial morphology in the cortex and hippocampus of FAD<sup>4T</sup> mice. Synaptic function was impaired in FAD<sup>4T</sup> mice. Patch clamp recordings of hippocampal neurons revealed reduced amplitude of miniature excitatory postsynaptic currents. Additionally, Golgi staining showed decreased dendritic spine density in the cortex and hippocampus of FAD<sup>4T</sup> mice, indicating aberrant synapse morphology. Moreover, hippocampal PSD-95 and NMDAR1 protein levels decreased in FAD<sup>4T</sup> mice. RNA-seq analysis revealed elevated expression of immune system and proinflammatory genes, including increased C1qA protein and mRNA levels, as well as higher expression of TNF-&#x3b1; and IL-18. Taken together, our findings suggest that excessive microglia activation mediated by complement factor C1qA may contribute to aberrant synaptic pruning, resulting in synapse loss and disrupted synaptic transmission, ultimately leading to AD pathogenesis and behavioral impairments in the FAD<sup>4T</sup> mouse model. Our study provides valuable insights into the underlying mechanisms of cognitive impairments and preliminarily explores a potentially effective treatment approach targeting on C1qA for AD.